LUCD Lucid Diagnostics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUCD

Price (delayed)

$0.8389

Market cap

$170.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$162.01M

?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 17
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 5
Highlights
Lucid Diagnostics's equity has soared by 173% from the previous quarter and by 39% YoY
The gross margin has surged by 63% year-on-year and by 31% since the previous quarter
The company's net income fell by 16% QoQ but it rose by 5% YoY
Sector: Healthcare
Industry: Medical Devices
Website: https://www.luciddx.com
Peers: ABT ISRG SYK BSX

Key stats

What are the main financial stats of LUCD

LUCD stock price

How has the Lucid Diagnostics stock price performed over time
Intraday
-6.02%
1 week
0.3%
1 month
-13%
1 year
-20.48%
YTD
-23.04%
QTD
-21.6%

Financial performance

How have Lucid Diagnostics's revenue and profit performed over time
Revenue
$5.45M
Gross profit
-$1.18M
Operating income
-$50.69M
Net income
-$52.26M
Gross margin
-21.7%
Net margin
-959.8%
The gross margin has surged by 63% year-on-year and by 31% since the previous quarter
LUCD's gross profit has soared by 54% year-on-year and by 27% since the previous quarter
LUCD's revenue is up by 25% year-on-year and by 6% since the previous quarter
Lucid Diagnostics's net margin has increased by 24% YoY but it has decreased by 9% QoQ

Price vs fundamentals

How does LUCD's price correlate with its fundamentals

Growth

What is Lucid Diagnostics's growth rate over time

Valuation

What is Lucid Diagnostics stock price valuation
P/E
N/A
P/B
15.59
P/S
28.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.75
The EPS has surged by 56% year-on-year
Lucid Diagnostics's equity has soared by 173% from the previous quarter and by 39% YoY
LUCD's P/B is 69% above its 5-year quarterly average of 9.8 but 25% below its last 4 quarters average of 22.2
The price to sales (P/S) is 50% lower than the 5-year quarterly average of 60.3 but 3.5% higher than the last 4 quarters average of 29.0
LUCD's revenue is up by 25% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Lucid Diagnostics business performance
The return on equity has surged by 74% year-on-year but it has declined by 5% since the previous quarter
Lucid Diagnostics's return on invested capital has shrunk by 68% YoY and by 38% QoQ
The ROA has increased by 28% YoY but it has decreased by 12% from the previous quarter
The return on sales has increased by 24% year-on-year but it has declined by 9% since the previous quarter

Dividends

What is LUCD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUCD.

Financial health

How did Lucid Diagnostics financials performed over time
Lucid Diagnostics's total assets is 39% higher than its total liabilities
The quick ratio is up by 29% since the previous quarter and by 17% year-on-year
Lucid Diagnostics's current ratio has increased by 24% from the previous quarter and by 16% YoY
Lucid Diagnostics's debt is 128% higher than its equity
Lucid Diagnostics's equity has soared by 173% from the previous quarter and by 39% YoY
The debt to equity has shrunk by 66% QoQ and by 35% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.